PVLA (Palvella Therapeutics) Beginning Cash Position: $57.98 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PVLA Palvella Therapeutics Inc PVLA
14 GF Score
Price $137.66
! 2 Warning Signs
View Full Analysis

What is Palvella Therapeutics Beginning Cash Position?

Palvella Therapeutics PVLA -3.45% 14 Beginning Cash Position is $57.98 Mil as of Mar. 2026. GuruFocus rates PVLA with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Palvella Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2026 was $57.98 Mil.

Palvella Therapeutics's quarterly Beginning Cash Position declined from Sep. 2025 ($70.43 Mil) to Dec. 2025 ($63.57 Mil) and declined from Dec. 2025 ($63.57 Mil) to Mar. 2026 ($57.98 Mil).

Palvella Therapeutics's annual Beginning Cash Position declined from Dec. 2023 ($16.05 Mil) to Dec. 2024 ($7.35 Mil) but then increased from Dec. 2024 ($7.35 Mil) to Dec. 2025 ($83.60 Mil).

Palvella Therapeutics Beginning Cash Position Related Terms

Palvella Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Palvella Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Palvella Therapeutics Beginning Cash Position Chart

Palvella Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
21.33 16.05 7.35 83.60

Palvella Therapeutics Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 83.60 75.63 70.43 63.57 57.98
PVLA
14GF Score
Palvella Therapeutics Inc PVLA
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Palvella Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $57.98 Mil mean?
Palvella Therapeutics (PVLA) has a Beginning Cash Position of $57.98 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Palvella Therapeutics and its competitors.
Is Palvella Therapeutics' Beginning Cash Position too high?
Palvella Therapeutics' current Beginning Cash Position is $57.98 Mil. Overall, Palvella Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Palvella Therapeutics' Beginning Cash Position compare to GENB and NKTR?
Palvella Therapeutics' Beginning Cash Position of $57.98 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Palvella Therapeutics and its competitors. Palvella Therapeutics's current Beginning Cash Position is $57.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Palvella Therapeutics stock overvalued right now?
Palvella Therapeutics (PVLA) has a current Beginning Cash Position of $57.98 Mil. The current Beginning Cash Position is $57.98 Mil. Palvella Therapeutics' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Palvella Therapeutics (PVLA), the current Beginning Cash Position is $57.98 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Palvella Therapeutics Business Description

Other Exchanges PI6:Germany
Address 353 W. Lancaster Avenue, Suite 200, Wayne, PA, USA, 19087
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
14GF Score

Get the complete analysis for PVLA

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$137.66
Price